June Harry
Primary Care · Redding, CANPI 1104384957
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 453 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 18.2% — the pattern of someone who eats at a lot of different presentations. Among primary care clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 453 payments — averaging $19.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$2K
- AbbVie$1K
- Boehringer Ingelheim$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Novo Nordisk$1K
- GSK$419
- plus $2K from 17 others
What the payments were for
- Food & beverage$8,869100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 78 | $1,612 |
| AbbVie | 85 | $1,438 |
| Boehringer Ingelheim | 45 | $1,266 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 75 | $1,122 |
| Novo Nordisk | 51 | $1,021 |
| GSK | 23 | $419 |
| AstraZeneca | 14 | $342 |
| Bayer | 11 | $285 |
| Pfizer | 12 | $235 |
| Idorsia Pharmaceuticals US Inc | 6 | $187 |
| Nestle Healthcare Nutrition Inc. | 13 | $173 |
| Biohaven Pharmaceutical Holding Company Ltd. | 10 | $153 |
| Sunovion Pharmaceuticals Inc. | 8 | $118 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $81 |
| Tandem Diabetes Care, Inc. | 1 | $73 |
| Amgen | 3 | $71 |
| Amarin Pharma, Inc. | 3 | $68 |
| Intercept Pharmaceuticals, Inc. | 3 | $58 |
| Almatica Pharma LLC | 3 | $57 |
| Biohaven Pharmaceuticals, Inc. | 2 | $35 |
| Abbott | 1 | $21 |
| Merck | 1 | $20 |
| Johnson & Johnson | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,869 in reported general payments places this provider in the 95th percentile of 706 primary care providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 348 | $251,997 |
| MounjaroTirzepatide | 187 | $198,453 |
| TrulicityDulaglutide | 96 | $99,501 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 68 | $50,355 |
| EliquisApixaban | 39 | $35,842 |
| KerendiaFinerenone | 19 | $23,623 |
| LinzessLinaclotide | 20 | $16,474 |
| OzempicSemaglutide | 18 | $15,576 |
| Tresiba Flextouch U-100Insulin Degludec | 16 | $8,587 |
| QuviviqDaridorexant Hcl | 11 | $5,472 |
| VascepaIcosapent Ethyl | 13 | $4,534 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 17 | $3,331 |
| Aripiprazole | 18 | $3,170 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 93 | $3,165 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 88 | $2,570 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $1,612 | $297,954283 claims |
| Boehringer IngelheimJardiance | $1,266 | $251,997348 claims |
| GSKTrelegy Ellipta | $419 | $50,35568 claims |
| PfizerEliquis | $235 | $35,84239 claims |
| BayerKerendia | $285 | $23,62319 claims |
| AbbVieLinzess, Synthroid, Armour Thyroid | $1,438 | $19,10061 claims |
| Novo NordiskOzempic | $1,021 | $15,57618 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $187 | $5,47211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 706 primary care providers in California.
Other primary care in Redding
- Leslie FletcherTorrance$1.8M
- Hamideh PourzandLos Angeles$103K
- Veronica RamirezSacramento$83K
- Tyson FieldstedBakersfield$65K
- Kathryn CooperSan Diego$31K
- Shalaine Corbillala Mesa$22K
- Paula StoddardHanford$22K
- Ashley LoweSan Diego$19K
- Vanessa LeeLong Beach$16K
- Lynda TranHuntington Beach$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.